Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Novo Nordisk

Status and phase

Completed

Phase 2

Conditions

Diabetes

Diabetes Mellitus, Type 2

Treatments

Drug: liraglutide

Drug: placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01508949

NN2211-1333

Details and patient eligibility

About

This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.

Enrollment

35 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes mellitus
Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
HbA1c for diet treated subjects 6.5-12%, both inclusive
HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%
Body mass index (BMI) at least 27 kg/m^2
Euthyroid subjects
Fasting blood glucose 7-14 mmol/l

Exclusion criteria

Impaired liver function
Impaired renal function
Cardiac problems
Uncontrolled treated/untreated hypertension
Recurrent severe hypoglycaemia as judged by the Investigator
Known or suspected allergy to trial product or related products
Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed